AR041548A1 - Celulas recombinantes modificadas (arcs) para la produccion y aplicacion de agentes antivirales, adyuvantes y acelerantes de vacunas - Google Patents

Celulas recombinantes modificadas (arcs) para la produccion y aplicacion de agentes antivirales, adyuvantes y acelerantes de vacunas

Info

Publication number
AR041548A1
AR041548A1 ARP030103652A ARP030103652A AR041548A1 AR 041548 A1 AR041548 A1 AR 041548A1 AR P030103652 A ARP030103652 A AR P030103652A AR P030103652 A ARP030103652 A AR P030103652A AR 041548 A1 AR041548 A1 AR 041548A1
Authority
AR
Argentina
Prior art keywords
arc
administration
modified recombinant
application
accelerants
Prior art date
Application number
ARP030103652A
Other languages
English (en)
Original Assignee
Dow Agrosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Agrosciences Llc filed Critical Dow Agrosciences Llc
Publication of AR041548A1 publication Critical patent/AR041548A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Abstract

Composiciones de citoquinas y/o quimiocinas activas, procesamiento y aplicación de composicones de citoquinas y/o quimiocinas activas. Métodos de tratamiento y métodos para acelerar una respuesta inmune que comprenden la administración de una célula recombinante modificada (ARC) que contiene composiciones de citoquinas y/o quimiocinas a animales o humasnos. Reivindicación 1: Una célula recombinante modificada (ARC) que comprende al menos un gen heterólogo que codifica una quimiocina o una citoquina. Reivindicación 3: La ARC de acuerdo con la reivindicación 2, en la cual el gen heterólogo codifica a IFN-gamma. Reivindicación 9: La ARC de acuerdo con la reivindicación 8, en la cual la célula microbiana es Pseudomonas fluorescens. Reivindicación 21: El método de acuerdo con la reivindicación 19, que comprende además la administración de un antígeno o inmunógeno antes de, en forma simultánea con, o con posterioridad a la administración de una composición de ARC. Reivindicación 29: El método de acuerdo con la reivindicación 28, que comprende además la administración de agentes quimioterapéuticos y, opcionalmente, antígenos de tumores o cáncer.
ARP030103652A 2002-10-08 2003-10-07 Celulas recombinantes modificadas (arcs) para la produccion y aplicacion de agentes antivirales, adyuvantes y acelerantes de vacunas AR041548A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41712402P 2002-10-08 2002-10-08

Publications (1)

Publication Number Publication Date
AR041548A1 true AR041548A1 (es) 2005-05-18

Family

ID=33131475

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103652A AR041548A1 (es) 2002-10-08 2003-10-07 Celulas recombinantes modificadas (arcs) para la produccion y aplicacion de agentes antivirales, adyuvantes y acelerantes de vacunas

Country Status (15)

Country Link
US (1) US7338794B2 (es)
EP (1) EP1549346A4 (es)
JP (1) JP4530858B2 (es)
KR (1) KR20050053749A (es)
CN (1) CN100594934C (es)
AR (1) AR041548A1 (es)
AU (1) AU2003304025B2 (es)
BR (1) BR0314542A (es)
CA (1) CA2501690C (es)
MX (1) MXPA05003692A (es)
NZ (1) NZ539207A (es)
PL (1) PL376343A1 (es)
RU (1) RU2335535C2 (es)
WO (1) WO2004087864A2 (es)
ZA (1) ZA200502746B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) * 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2005069913A2 (en) 2004-01-16 2005-08-04 Dow Global Technologies Inc. Expression of mammalian proteins in pseudomonas fluorescens
BRPI0513826A2 (pt) 2004-07-26 2010-06-22 Dow Global Technologies Inc processo para expressão de proteìna melhorada através de engenharia de cepa
US20080274140A1 (en) * 2004-11-19 2008-11-06 David B Weiner Vaccines and Methods for Using the Same
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN101688213A (zh) 2007-04-27 2010-03-31 陶氏环球技术公司 用于快速筛选微生物宿主以鉴定某些在表达异源蛋白质方面具有改善的产量和/或质量的菌株的方法
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
AR084293A1 (es) 2010-12-16 2013-05-08 Dow Agrosciences Llc Cry1FA RADIOMARCADA, BIOLOGICAMENTE ACTIVA Y METODOS DE ENSAYOS DE UNION AL RECEPTOR
WO2012135786A2 (en) * 2011-04-01 2012-10-04 The Regents Of The University Of California Cryoelectric systems and methods for treatment of biological matter
US10428112B2 (en) * 2014-06-11 2019-10-01 Riken Multiplexed same type-antigenic peptide
KR101825439B1 (ko) 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
CN108815518A (zh) * 2018-09-19 2018-11-16 天津瑞普生物技术股份有限公司 一种鸡传染性法氏囊病亚单位疫苗及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
US5281532A (en) * 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
EP0168008A3 (en) * 1984-07-10 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
US4695455A (en) * 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4695462A (en) * 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
US6121247A (en) * 1996-03-29 2000-09-19 The Johns Hopkins University Therapy for allergic diseases
WO2002064159A1 (en) * 2001-02-07 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Remedies for tumor in hematopoietic organs

Also Published As

Publication number Publication date
PL376343A1 (en) 2005-12-27
CA2501690A1 (en) 2004-10-14
US20040146484A1 (en) 2004-07-29
BR0314542A (pt) 2005-07-26
CA2501690C (en) 2012-04-03
ZA200502746B (en) 2006-01-25
JP2006510388A (ja) 2006-03-30
WO2004087864A3 (en) 2004-12-23
KR20050053749A (ko) 2005-06-08
MXPA05003692A (es) 2005-09-30
CN100594934C (zh) 2010-03-24
US7338794B2 (en) 2008-03-04
EP1549346A2 (en) 2005-07-06
NZ539207A (en) 2006-10-27
AU2003304025B2 (en) 2009-02-19
JP4530858B2 (ja) 2010-08-25
RU2335535C2 (ru) 2008-10-10
EP1549346A4 (en) 2008-04-23
AU2003304025A1 (en) 2004-10-25
CN1723040A (zh) 2006-01-18
RU2005114012A (ru) 2006-01-20
WO2004087864A2 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
AR041548A1 (es) Celulas recombinantes modificadas (arcs) para la produccion y aplicacion de agentes antivirales, adyuvantes y acelerantes de vacunas
ES2528384T3 (es) Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación
UY27465A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides
CO5680108A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
ES2139879T3 (es) Adyuvante de la mucosa no toxico.
AR069722A1 (es) Vacuna contra escherichia coli enterohemorragica
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
MXPA05007821A (es) Terapia de combinacion para tratar deficiencias de proteinas.
Ritter et al. The control of Leishmania (Leishmania) major by TNF in vivo is dependent on the parasite strain
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
Stasiłojć et al. Recombinant Bacillus subtilis spores elicit Th1/Th17-polarized immune response in a murine model of Helicobacter pylori vaccination
WO2002088328A3 (en) Method for generating highly active human dendritic cells from monocytes
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
AU2599002A (en) Fusion cells and cytokine compositions for treatment of disease
PL372314A1 (en) Dna vaccine against proliferating endothelial cells and methods of use thereof
Mohammadzadeh et al. Canola oilseed‐and Escherichia coli‐derived hepatitis C virus (HCV) core proteins adjuvanted with oil bodies, induced robust Th1‐oriented immune responses in immunized mice
MX2022011867A (es) Xantenos halogenados como adyuvantes en vacunas.
WO2003039592A3 (de) Zelluläre impfstoffe mit adjuvanzien
DK1509244T3 (da) Ny fremgangsmåde og præparat til at producere en cellulær allogen vaccine
EA200700017A1 (ru) Способ усиления иммунного ответа на вакцину
WO2003093298A3 (en) Immunogenic peptides
WO2023159136A3 (en) Epitope engineering of cell-surface receptors
WO2004018002A3 (en) Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells
AU2003240790A1 (en) Antibody peg positional isomers, compositions comprising same, and use thereof

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee